Beazer Homes USA Inc (BZH)

16.24
0.07 0.43
NYSE : Industrial Goods
Prev Close 16.31
Open 16.25
Day Low/High 16.09 / 16.35
52 Wk Low/High 9.67 / 16.47
Volume 45.00K
Avg Volume 456.90K
Exchange NYSE
Shares Outstanding 33.54M
Market Cap 540.61M
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Housing Market Better Than Data Show, Lennar Says as It Beats Estimates and Its Shares Rise

Housing Market Better Than Data Show, Lennar Says as It Beats Estimates and Its Shares Rise

The results were 16 percent ahead of the 79 cents a share Wall Street consensus estimate as compiled by FactSet.

Interesting BZH Put And Call Options For February 2018

Investors in Beazer Homes USA, Inc. saw new options become available today, for the February 2018 expiration.

Housing Data Drives Down Homebuilding Stocks

Housing Data Drives Down Homebuilding Stocks

Beazer, Standard Pacific, and Hovnanian fell the furthest this morning.

Relaxed Credit Standards at Fannie Mae Could Be a Jolt for This Homebuilder

Relaxed Credit Standards at Fannie Mae Could Be a Jolt for This Homebuilder

Wedbush analyst Jay McCanless argues that the Atlanta-based homebuilder will enter a growth phase in 2018.

Analysts' Actions -- Beazer Homes, Chevron, Ecolab, Sherwin-Williams and More

Analysts' Actions -- Beazer Homes, Chevron, Ecolab, Sherwin-Williams and More

Here are Friday's top research calls, including downgrades for Beazer Homes and Chevron, an upgrade for Ecolab and new coverage of Sherwin-Williams.

My Housing Logic Conundrum

My Housing Logic Conundrum

Loan rates and yields should be headed lower.

Small Homebuilders Are Tempting

Small Homebuilders Are Tempting

Homebuilders are the second-largest allocation within my biotech.

Beazer Homes Reports Strong Second Quarter Fiscal 2017 Results

Beazer Homes USA, Inc. (NYSE: BZH) ( www.

The Real Issue With Housing and the Fed

The Real Issue With Housing and the Fed

Trimming the Fed's balance sheet raises questions about what FOMC members know about the economy.

Beazer Enters A National Exclusive Agreement With Mohawk To Include All Flooring Categories

Beazer Homes USA, Inc. (NYSE: BZH), one of the nation's largest home builders, today announced Mohawk Industries (NYSE: MHK) as its exclusive product supplier across all flooring categories, including carpet, ceramic tile,...

Beazer Homes Earns 2017 ENERGY STARĀ® Partner Of The Year - Sustained Excellence Award

Beazer Homes (NYSE: BZH) has been named a 2017 ENERGY STAR Partner of the Year - Sustained Excellence Award winner for continued leadership in protecting our environment through superior energy efficiency achievements.

Spring Housing Market Is Set to Surge

Spring Housing Market Is Set to Surge

But not for the reasons you might expect.

Beazer Homes USA Becomes Oversold (BZH)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Beazer Homes Announces Closing Of Offering Of $250 Million Senior Unsecured Notes Due 2025

Beazer Homes USA, Inc. (NYSE: BZH) (the "Company") announced today the completion of its previously-announced offering of $250 million aggregate principal amount of 6.

Beazer Homes Announces Results Of Tender Offer For 7.500% Senior Notes Due 2021

Beazer Homes USA, Inc. (NYSE: BZH) (the "Company") announced today the results of its previously announced cash tender offer for any and all of its 7.

Beazer Homes Announces Pricing Of Offering Of $250 Million Of Senior Unsecured Notes

Beazer Homes USA, Inc. (NYSE: BZH) (the "Company") today priced an offering of $250 million aggregate principal amount of 6.

Beazer Homes Announces Proposed Offering Of $250 Million Of Senior Notes

Beazer Homes USA, Inc. (NYSE: BZH) (the "Company") announced today that it is proposing to issue $250 million aggregate principal amount of Senior Notes due 2025 (the "Notes") in a private offering that is exempt from the...

Beazer Homes Announces Preliminary Operating Results

Beazer Homes USA, Inc. (NYSE:BZH) (the "Company") today announced that its sales absorptions for the first two months of its fiscal second quarter were up 11% year over year, resulting in 1,001 orders compared to 1,003 in...

Beazer Homes Announces Tender Offer For 7.500% Senior Notes Due 2021

Beazer Homes USA, Inc. (NYSE: BZH) (the "Company") announced today that it has commenced a cash tender offer for any and all of its 7.

Commit To Buy Beazer Homes USA At $8, Earn 6.2% Annualized Using Options

Investors considering a purchase of Beazer Homes USA, Inc. shares, but tentative about paying the going market price of $12.17/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Market Recon: This Barbarous Relic Has Been Seriously Hot Lately

Market Recon: This Barbarous Relic Has Been Seriously Hot Lately

We have a president that seems likely to pursue a weaker dollar policy, and gold has surged.

Beazer Homes Reports First Quarter Fiscal 2017 Results

Beazer Homes USA, Inc. (NYSE: BZH) ( www.

Beazer Homes Again Partners With The Marine Toys For Tots Foundation For Guess To Give Campaign

Beazer Homes Again Partners With The Marine Toys For Tots Foundation For Guess To Give Campaign

Beazer Homes, one of the nation's largest home builders, partnered with the Marine Toys for Tots Foundation for a second year to collect toys and raise awareness of the group's mission to deliver hope to deserving children.

There's No Pent-Up Housing Demand

There's No Pent-Up Housing Demand

Consumer confidence is up, but savings is down, which will curb first-time buyers' housing demand.

My Top 2017 Pick: Progenics Pharmaceuticals

My Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher this year.

Top 2017 Pick: Progenics Pharmaceuticals

Top 2017 Pick: Progenics Pharmaceuticals

This biopharma company's Relistor drug should send revenues sharply higher next year.